The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2017 | How to discuss immunotherapy as a treatment option with lung cancer patients
Rolf A. Stahel, MD, University Hospital Zürich, Zürich, Switzerland, provides advice on how to discuss immunotherapy as a second-line treatment option for patients with lung cancer. He highlights that approximately 1in 6 to 1 in 5 patients benefit from the treatment and that this should be clearly communicated to patients.
Recorded at the 2017 meeting of the British Thoracic Oncology Group (BTOG) in Dublin, Ireland.
